LONDON & WILMINGTON, N.C.--(BUSINESS WIRE)--Chiltern, a leading, global contract research organization, will be exhibiting at the CHI SCOPE Summit in Miami, Feb. 23-25, and providing a key executive for a session on risk-based monitoring (RBM).
Melissa Nezos, executive director of clinical operations for North America at Chiltern, will join Gareth Adams, founder and executive consultant at Synaid Consulting, to co-present “The Evolution of Clinical Operations and Data Management — The Biggest ‘Risk’ in Risk-Based Monitoring?” The presentation will be during the second session of the Implementing Risk-Based Monitoring track.
Nezos and Adams will share lessons learned in developing new roles, analytics and processes in order to implement a variety of RBM strategies with a no-one-size-fits-all strategy. “Most clinical trials have historically been conducted with a reactive monitoring strategy,” says Nezos, “but our experience has shown that trials that use RBM methods are safer for patients and produce better data. Gareth and I are excited to explain all of the benefits of a proactive approach to clinical trials.” The presentation will be at 4:55 p.m. Feb. 24.
Chiltern will be exhibiting at Booth 605 at CHI SCOPE Summit and will be available for meetings. Stop by the booth or schedule a meeting with the team.
Chiltern is the leading, global mid-sized contract research organization that listens to client needs to deliver customized clinical development solutions. Chiltern’s team of more than 4,000 works across 47 countries to provide comprehensive, yet flexible and responsive, services, with specialties in Clinical Development, Oncology, Device & Diagnostics, Data, Analytics & Evaluation and Strategic Service Provision. Visit Chiltern.com to learn more about solutions that are Designed Around You®.